IDEAYA Biosciences, Inc. Operating Expenses
IDEAYA Biosciences, Inc. (IDYA) reported Operating Expenses of $131.15 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-04
- IDEAYA Biosciences, Inc. operating expenses for the quarter ending 2026-06-30 was $131.15M, a 47.68% increase year-over-year.
- IDEAYA Biosciences, Inc. operating expenses for the quarter ending 2026-03-31 was $115.10M, a 36.40% increase year-over-year.
- IDEAYA Biosciences, Inc. operating expenses for the quarter ending 2025-12-31 was $105.45M, a 30.23% decline year-over-year.
- IDEAYA Biosciences, Inc. operating expenses for the quarter ending 2025-09-30 was $99.38M, a 48.57% increase year-over-year.
- IDEAYA Biosciences, Inc. operating expenses for fiscal 2025 was $378.02M, a 13.19% increase from fiscal 2024.
- IDEAYA Biosciences, Inc. operating expenses for fiscal 2024 was $333.98M, a 111.63% increase from fiscal 2023.
- IDEAYA Biosciences, Inc. operating expenses for fiscal 2023 was $157.81M, a 39.13% increase from fiscal 2022.
- IDEAYA Biosciences, Inc. operating expenses for fiscal 2022 was $113.43M, a 45.04% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $131.15M 10-Q · filed 2026-08-04 | $246.25M 10-Q · filed 2026-08-04 | $351.70M derived: sum of 3 quarters · filed 2026-08-04 | $451.08M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $115.10M 10-Q · filed 2026-05-05 | $220.55M derived: sum of 2 quarters · filed 2026-05-05 | $319.93M derived: sum of 3 quarters · filed 2026-05-05 | $408.74M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $105.45M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $204.83M derived: sum of 2 quarters · filed 2026-02-17 | $293.63M derived: sum of 3 quarters · filed 2026-08-04 | $378.02M 10-K · filed 2026-02-17 |
| 2025-09-30 | $99.38M 10-Q · filed 2025-11-04 | $188.19M derived: sum of 2 quarters · filed 2026-08-04 | $272.58M 10-Q · filed 2025-11-04 | $423.71M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $88.81M 10-Q · filed 2026-08-04 | $173.19M 10-Q · filed 2026-08-04 | $324.33M derived: sum of 3 quarters · filed 2026-08-04 | $391.23M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $84.39M 10-Q · filed 2026-05-05 | $235.53M derived: sum of 2 quarters · filed 2026-05-05 | $302.42M derived: sum of 3 quarters · filed 2026-05-05 | $367.35M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $151.14M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $218.03M derived: sum of 2 quarters · filed 2026-02-17 | $282.96M derived: sum of 3 quarters · filed 2026-02-17 | $333.98M 10-K · filed 2026-02-17 |
| 2024-09-30 | $66.89M 10-Q · filed 2025-11-04 | $131.82M derived: sum of 2 quarters · filed 2025-11-04 | $182.84M 10-Q · filed 2025-11-04 | $228.68M derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-06-30 | $64.93M 10-Q · filed 2025-08-05 | $115.94M 10-Q · filed 2025-08-05 | $161.78M derived: sum of 3 quarters · filed 2026-02-17 | $203.35M derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-03-31 | $51.02M 10-Q · filed 2025-05-06 | $96.86M derived: sum of 2 quarters · filed 2026-02-17 | $138.42M derived: sum of 3 quarters · filed 2026-02-17 | $174.67M derived: sum of 4 quarters · filed 2026-02-17 |
| 2023-12-31 | $45.84M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $87.40M derived: sum of 2 quarters · filed 2026-02-17 | $123.66M derived: sum of 3 quarters · filed 2026-02-17 | $157.81M 10-K · filed 2026-02-17 |
| 2023-09-30 | $41.56M 10-Q · filed 2024-11-04 | $77.82M derived: sum of 2 quarters · filed 2024-11-04 | $111.97M 10-Q · filed 2024-11-04 | $142.44M derived: sum of 4 quarters · filed 2025-02-18 |
| 2023-06-30 | $36.25M 10-Q · filed 2024-08-06 | $70.41M 10-Q · filed 2024-08-06 | $100.88M derived: sum of 3 quarters · filed 2025-02-18 | $129.92M derived: sum of 4 quarters · filed 2025-02-18 |
| 2023-03-31 | $34.16M 10-Q · filed 2024-05-07 | $64.62M derived: sum of 2 quarters · filed 2025-02-18 | $93.66M derived: sum of 3 quarters · filed 2025-02-18 | $122.01M derived: sum of 4 quarters · filed 2025-02-18 |
| 2022-12-31 | $30.46M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-18 | $59.50M derived: sum of 2 quarters · filed 2025-02-18 | $87.85M derived: sum of 3 quarters · filed 2025-02-18 | $113.43M 10-K · filed 2025-02-18 |
| 2022-09-30 | $29.04M 10-Q · filed 2023-11-07 | $57.39M derived: sum of 2 quarters · filed 2023-11-07 | $82.97M 10-Q · filed 2023-11-07 | $104.30M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-06-30 | $28.35M 10-Q · filed 2023-08-10 | $53.93M 10-Q · filed 2023-08-10 | $75.26M derived: sum of 3 quarters · filed 2024-02-20 | $95.95M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-03-31 | $25.58M 10-Q · filed 2023-05-09 | $46.91M derived: sum of 2 quarters · filed 2024-02-20 | $67.60M derived: sum of 3 quarters · filed 2024-02-20 | $87.41M derived: sum of 4 quarters · filed 2024-02-20 |
| 2021-12-31 | $21.33M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $42.02M derived: sum of 2 quarters · filed 2024-02-20 | $61.83M derived: sum of 3 quarters · filed 2024-02-20 | $78.21M 10-K · filed 2024-02-20 |
| 2021-09-30 | $20.69M 10-Q · filed 2022-11-08 | $40.50M derived: sum of 2 quarters · filed 2022-11-08 | $56.88M 10-Q · filed 2022-11-08 | $72.73M derived: sum of 4 quarters · filed 2023-03-07 |
| 2021-06-30 | $19.81M 10-Q · filed 2022-08-15 | $36.19M 10-Q · filed 2022-08-15 | $52.04M derived: sum of 3 quarters · filed 2023-03-07 | $66.00M derived: sum of 4 quarters · filed 2023-03-07 |
| 2021-03-31 | $16.38M 10-Q · filed 2022-05-10 | $32.23M derived: sum of 2 quarters · filed 2023-03-07 | $46.20M derived: sum of 3 quarters · filed 2023-03-07 | $58.79M derived: sum of 4 quarters · filed 2023-03-07 |
| 2020-12-31 | $15.85M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-07 | $29.81M derived: sum of 2 quarters · filed 2023-03-07 | $42.40M derived: sum of 3 quarters · filed 2023-03-07 | $54.88M 10-K · filed 2023-03-07 |
| 2020-09-30 | $13.96M 10-Q · filed 2021-11-15 | $26.55M derived: sum of 2 quarters · filed 2021-11-15 | $39.03M 10-Q · filed 2021-11-15 | $50.35M derived: sum of 4 quarters · filed 2021-11-15 |
| 2020-06-30 | $12.59M 10-Q · filed 2021-08-10 | $25.07M 10-Q · filed 2021-08-10 | $36.39M derived: sum of 3 quarters · filed 2021-08-10 | $48.01M derived: sum of 4 quarters · filed 2021-08-10 |
| 2020-03-31 | $12.48M 10-Q · filed 2021-05-10 | $23.80M derived: sum of 2 quarters · filed 2021-05-10 | $35.42M derived: sum of 3 quarters · filed 2021-05-10 | $46.66M derived: sum of 4 quarters · filed 2021-05-10 |
| 2019-12-31 | $11.32M 10-K · filed 2020-03-24 | $22.94M derived: sum of 2 quarters · filed 2020-11-12 | $34.18M derived: sum of 3 quarters · filed 2020-11-12 | $44.27M 10-K · filed 2022-03-18 |
| 2019-09-30 | $11.62M 10-Q · filed 2020-11-12 | $22.86M derived: sum of 2 quarters · filed 2020-11-12 | $32.95M 10-Q · filed 2020-11-12 | $42.09M derived: sum of 4 quarters · filed 2020-11-12 |
| 2019-06-30 | $11.23M 10-Q · filed 2020-08-12 | $21.33M 10-Q · filed 2020-08-12 | $30.46M derived: sum of 3 quarters · filed 2020-08-12 | $44.09M derived: sum of 4 quarters · filed 2020-08-12 |
| 2019-03-31 | $10.09M 10-Q · filed 2020-05-12 | $19.23M derived: sum of 2 quarters · filed 2020-05-12 | $32.85M derived: sum of 3 quarters · filed 2020-05-12 | $40.42M derived: sum of 4 quarters · filed 2020-05-12 |
| 2018-12-31 | $9.13M 10-K · filed 2020-03-24 | $22.76M derived: sum of 2 quarters · filed 2020-03-24 | $30.33M derived: sum of 3 quarters · filed 2020-03-24 | $36.42M 10-K · filed 2021-03-23 |
| 2018-09-30 | $13.63M 10-K · filed 2020-03-24 | $21.20M derived: sum of 2 quarters · filed 2020-03-24 | $27.28M 10-Q · filed 2019-11-13 | |
| 2018-06-30 | $7.57M 10-K · filed 2020-03-24 | $13.66M 10-Q · filed 2019-08-12 | ||
| 2018-03-31 | $6.09M 10-K · filed 2020-03-24 | |||
| 2017-12-31 | $14.44M 10-K · filed 2020-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |